| Dr Mary Jane Mcclements, MD | |
|
21 W Clarke Ave, Milford, DE 19963-1840 | |
| (302) 430-5435 | |
| (302) 430-5644 |
| Full Name | Dr Mary Jane Mcclements |
|---|---|
| Gender | Female |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 21 W Clarke Ave, Milford, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891776704 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | C1-0007002 (Delaware) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mary Jane Mcclements, MD 21 W Clarke Ave, Milford, DE 19963-1840 Ph: (302) 430-5435 | Dr Mary Jane Mcclements, MD 21 W Clarke Ave, Milford, DE 19963-1840 Ph: (302) 430-5435 |
News Archive
Elan Corporation, plc announced today that it has commenced planned measures to reduce its indebtedness using the cash proceeds received in connection with the combination of its EDT business with Alkermes Inc., which closed today.
In the decade since the introduction of pneumococcal vaccination, significant shifts have occurred in the bacterial strains causing serious pneumococcal infections in children, according to a pair of studies in the April issue of The Pediatric Infectious Disease Journal (www.PIDJ.com). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.
Results of a European study in this week's issue of THE LANCET suggest that delaying delivery by a few days is as effective as immediate delivery for babies who have experienced fetal trauma. The study also showed that fetuses delivered without delay at 30 weeks or younger had an increased risk of infant disability compared with delayed delivery.
Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.
A once-daily medication option for treating the most common mouth infection in HIV/AIDS patients has shown to be just as effective and safe as taking an anti-fungal pill five times a day, according to a Henry Ford Hospital study.
› Verified 3 days ago